Clinical trials: Lymphomas,
Diffuse Large B-cell Lymphoma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00474188
- Testing
- CC-5013 (lenalidomide), dexamethasone
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene Corporation
Cutaneous T-Cell Lymphoma
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy
- Trial name
- NCT06285370
- Testing
- Mogamulizumab
- Where
- 8 sites in China
- Volunteers
- 23 people
- Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
Non-Hodgkin's Lymphoma
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).
- Trial name
- NCT00042666
- Testing
- LY317615
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Leukemia, Lymphocytic, Chronic, B-Cell
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in combination with ibrutinib and obinuzutumab. CC-122 has multiple activities, including immune modulation of several immune cell subsets and…
- Trial name
- ENHANCE (NCT02406742)
- Testing
- CC-122, Ibrutinib, Obinutuzumab
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 47 people
- Sponsor
- Celgene
Lymphoma
Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
RATIONALE: Inserting the gene for RevM10 into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
- Trial name
- NCT00003942
- Testing
- RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Systemix
Neoplasms
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
This is an open-label repeat dose, multicenter, 2-part study to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily (QD) orally.
- Trial name
- NCT01943851
- Testing
- GSK525762
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 111 people
- Sponsor
- GlaxoSmithKline
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
FT819 in Subjects With B-cell Malignancies
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia.
- Conditions
- Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04629729
- Testing
- FT819, Cyclophosphamide, Fludarabine
- Where
- 18 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fate Therapeutics
Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
SUBLOCADE Rapid Initiation Extension Study
A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.
- Trial name
- NCT04060654
- Testing
- Sublocade
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indivior Inc.
Follicular Lymphoma
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
The primary objective of the current study is to demonstrate the equivalent efficacy of rituximab (DRL_RI) and MabThera® in subjects with Low Tumor Burden Follicular Lymphoma (LTB-FL).
- Trial name
- FLINTER (NCT03976102)
- Testing
- DRL_RI (Proposed rituximab biosimilar), MabThera®
- Where
- 4 sites in United States
- Volunteers
- 317 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Lymphoma, Non-Hodgkin
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
- Trial name
- NCT03930953
- Testing
- CC-99282, Rituximab, Obinutuzumab
- Where
- 66 sites in United States, Argentina and 13 more
- Volunteers
- 438 people
- Sponsor
- Celgene
Diffuse Large B-Cell Lymphoma
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Primary Objective: Participants Achieving an Objective Response Rate (Cheson 2007) Secondary Objectives: Progression Free Survival Overall Survival Response Duration
- Trial name
- NCT01470456
- Testing
- SAR3419, rituximab
- Where
- 13 sites in Austria, France and 1 more
- Volunteers
- 50 people
- Sponsor
- Sanofi
Diffuse Large Cell B-lymphoma
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
- Trial name
- NCT06854445
- Testing
- TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection
- Where
- 24 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Diffuse Large B-Cell Lymphoma
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
- Trial name
- GlofitReal (NCT07200375)
- Testing
- Glofitamab
- Where
- 22 sites in China, Hong Kong
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.
- Trial name
- NCT03684694
- Testing
- Loncastuximab Tesirine, Ibrutinib
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 136 people
- Sponsor
- ADC Therapeutics S.A.
Relapsed/Refractory Large B Cell Lymphoma
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to…
- Trial name
- EXPAND (NCT05714345)
- Testing
- ALLO-647, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States, Belgium
- Volunteers
- 2 people
- Sponsor
- Allogene Therapeutics
Lymphoma, Non-Hodgkin, Hodgkin's Lymphoma
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
- Trial name
- NCT00061672
- Testing
- ABT-510 - Thrombospondin-1 Mimetic
- Where
- 14 sites in United States
- Volunteers
- 67 people
- Sponsor
- Abbott
Peripheral T-cell Lymphoma
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma…
- Trial name
- PRIMO (NCT03372057)
- Testing
- Duvelisib
- Where
- 36 sites in United States, Germany and 3 more
- Volunteers
- 156 people
- Sponsor
- SecuraBio
Cutaneous T-cell Lymphoma
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
This phase II study is designed to determine the efficacy and safety of APO866 for the treatment of patients with advanced forms of cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00431912
- Testing
- APO866
- Where
- 5 sites in Austria, France and 2 more
- Volunteers
- 25 people
- Sponsor
- Valerio Therapeutics
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Marginal Zone
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 when administered in East Asian participants with NHL who do not have an effective…
- Trial name
- NCT03238651
- Testing
- TAK-659
- Where
- 4 sites in Japan, South Korea
- Volunteers
- 17 people
- Sponsor
- Calithera Biosciences, Inc
Plasma Cell Disorder
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
Multi-site, prospective performance study to determine equivalency between the investigational OneFlow PCD panel on the FACSLyric system versus the final clinical diagnosis.
- Trial name
- NCT05032339
- Testing
- IUO Plasma Cell Disorders Panel
- Where
- 5 sites in United States, Portugal and 3 more
- Volunteers
- 208 people
- Sponsor
- Becton, Dickinson and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.